Cannabis Companies Partner To Provide Seed-to-Pharma Products Globally
Portfolio Pulse from Patricio Liddle
Benuvia Operations LLC and PharmaCielo Ltd (OTCQX:PCLOF) (TSXV:PCLO) have announced a strategic partnership to manufacture CGMP pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) for the global market. PharmaCielo will cultivate cannabis and hemp in Colombia, while Benuvia will produce the final product in Texas. The partnership aims to offer Seed-to-Pharma products globally, ensuring quality and compliance. PharmaCielo also plans to issue common shares to satisfy interest payments on debentures. PCLOF's shares were trading at $0.107 at the time of the announcement.
January 04, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmaCielo's partnership with Benuvia to produce pharmaceutical-grade cannabis products may boost investor confidence in its growth and market expansion, potentially impacting the stock positively.
The strategic partnership with Benuvia is likely to be viewed positively as it expands PharmaCielo's capabilities and market reach. The focus on CGMP and EU-GMP compliance could attract investors looking for companies with high-quality standards. The issuance of common shares for interest payments shows active financial management, although it may dilute current shareholders' value. Overall, the news is likely to have a positive short-term impact on PCLOF's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100